Sovran Advisors LLC Buys Shares of 27,015 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sovran Advisors LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 27,015 shares of the biotechnology company’s stock, valued at approximately $3,210,000.

Other institutional investors have also recently bought and sold shares of the company. Simplify Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after purchasing an additional 88,474 shares during the period. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after acquiring an additional 116,800 shares in the last quarter. Larson Financial Group LLC boosted its position in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the period. Finally, abrdn plc increased its holdings in Sarepta Therapeutics by 30.7% in the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Finally, Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $112.74 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm’s 50 day moving average is $120.82 and its 200-day moving average is $125.57. Sarepta Therapeutics, Inc. has a 12-month low of $102.15 and a 12-month high of $173.25. The stock has a market capitalization of $10.77 billion, a P/E ratio of 90.19 and a beta of 0.75.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.